Skip to main content
JAMA internal medicine
Health policy update 2014: another exciting and turbulent year ahead.
The high price of the new hepatitis C virus drugs.
Hospital admissions for hypoglycemia now exceed those for hyperglycemia in Medicare beneficiaries.
Developing methods for less is more.
Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
The importance of postapproval data for dabigatran.
A new program for sharing medical cost information.
Cardiac patient outcomes during national cardiology meetings.
Stress testing in the emergency department: not which test but whether any test should be done.
